Pharma Patrice Carayon, CEO of Chiesi France, reveals how Chiesi is one of a select few international mid-size pharmaceutical companies in France to have both an R&D and production footprint to accompany its commercial activities; how they will look to continue to establish themselves in their three main areas: respiratory diseases,…
Chiesi Chiesi is preparing to market two first in class products: the first approved stem cell treatment in Europe, and the first approved gene-therapy, developed in the Netherlands by partner UniQure. General Manager Nether Maurits Huigen discusses the challenges his affiliate is facing to bringing these pioneering products to market, along…
Chiesi Turkey is quickly becoming a regional hub for pharmaceutical industry for management, clinical trials and manufacturing, explains the general manager of Chiesi Turkey. How important is it for the government to clarify the incentives that have been discussed? The healthcare system in Turkey has undergone the largest transition in its…
Chiesi Internationalization and innovation are part of Chiesi’s history. The general manager of the recently started Mexican affiliate discusses the company’s priorities for the second largest market in Latin America and how the company plans to strengthen its presence through a portfolio of life-saving and innovative products. Chiesi started operations in…
Chiesi Brazil Yesterday, Minister Pimentel unveiled the Brazil Maior plan to increase competitiveness and growth across a variety of industrial sectors. If you had to give recommendations to improve the Brazilian pharmaceutical sector, what would they be? That is an extremely difficult question. I believe it is better to support two kinds…
Chiesi Pharmaceuticals BV The Dutch affiliate of Chiesi was established in 2007 when many changes were occurring in the local industry. The new healthcare system policy went into effect and the market was shifting towards a cost-containment structure. What drove Chiesi’s decision to start-up in the Netherlands? Our respiratory product, Foster, was one…
Torrex Chiesi Poland Would you begin by explaining to the readers of Pharmaceutical Executive the importance of the operation in Poland for the company? Indeed Poland because of largest in CEE pharmaceutical market size was always very attractive for all pharmaceutical companies, although it is a very complex market. For those coming to…
Chiesi France The basis of the pharmaceutical business model is changing. Take sales forces for instance, what will be the composition and daily routine? How much mixed media will it require? Currently, there is a schizophrenic state in to the market in between biotechnologies and generics. This is a clear case of…
See our Cookie Privacy Policy Here